Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials

Breast Cancer

Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial

J Clin Oncol

Yamashita T, Saji S, Takano T, Naito Y, Tsuneizumi M, Yoshimura A, Takahashi M, Tsurutani J, Iwatani T, Kitada M, Tada H, Mori N, Higuchi T, Iwasa T, Araki K, Koizumi K, Hasegawa H, Uchida Y, Morita S, Masuda N

doi: 10.1200/JCO-24-01888

Breast Cancer

Human Epidermal Growth Factor Receptor 2 Loss Following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer

Clin Cancer Res

Gouda MA, Gonugunta A, Dumbrava EE, Yap TA, Rodon J, Piha-Paul SA, Pohlmann PR, Damodaran S, Murthy R, Valero V, Mouabbi J, Tripathy D, Sahin AA, Chen H, Meric-Bernstam F

doi: 10.1158/1078-0432.CCR-24-3468

Breast Cancer

Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: A systematic review and updated meta-analysis

Cancer Treat Rev

Michelon I, Castro CER, Madeira T, Dacoregio MI, Stecca C, Soares LR, Saeed A, Vilbert M, Cavalcante L

doi: 10.1016/j.ctrv.2025.102882

Gastrointestinal Cancer

FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials

Eur J Cancer

Antoniotti C, Marmorino F, Rossini D, Schmoll HJ, Lonardi S, Tonini G, Borelli B, Cupini S, Stein A, Moretto R, Bergamo F, Ronzoni M, Germani MM, Zaniboni A, Fazio R, De Grandis MC, Ongaro E, Masi G, Cremolini C

doi: 10.1016/j.ejca.2025.115713

Lung, Respiratory and Thoracic Cancer

Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834

J Clin Oncol

Miura S, Tanaka H, Misumi T, Yoshioka H, Tokito T, Fukuhara T, Sato Y, Shiraishi Y, Naoki K, Akamatsu H, Yamaguchi O, Yokoyama T, Kuyama S, Nishino K, Furuya N, Kurata T, Kato T, Ikeda S, Horinouchi H, Ichihara E, Mori M, Takiguchi Y, Tanaka K, Goto Y, Okamoto H, Thoracic Oncology Research Group and all ACHILLES investigators

doi: 10.1200/JCO-24-02007

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer

Chouaid C, Bosquet L, Knott C, Li Z, Schaeffer M, Lin X, Schioppa CA, Perualila NJ, Diels J, Caparros EQ, Galea F, Hultén A, Greystoke A

doi: 10.1016/j.lungcan.2025.108548

Gastrointestinal Cancer

Impact of trifluridine/tipiracil plus bevacizumab on tumor shrinkage and depth of response in refractory metastatic colorectal cancer: analysis of the SUNLIGHT trial

Eur J Cancer

Taieb J, Modest DP, Fakih M, Ciardiello F, Van Cutsem E, Elez E, Gravalos C, Bragagnoli AC, Barboux V, Roby L, Amellal N, Prager GW

doi: 10.1016/j.ejca.2025.115644

Gastrointestinal Cancer

Prospective validation of the modified metastatic colorectal cancer score (mCCS) in >600 patients with RAS-wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATE

Int J Cancer

Potthoff K, Uhlig J, Jacobasch L, Müller L, Reiser M, de Buhr R, Polata S, Gerger A, Zehrer V, Amann A, Göhler T, Serrer L, Schröder J, Semsek D, Köhler A, Stübs P, Prager G, Siebenbach HU, Schuch A, Marschner N

doi: 10.1002/ijc.70139

Breast Cancer

Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials

Eur J Cancer

Hart LL, Im SA, Tolaney SM, Campone M, Pluard T, Sousa B, Freyer G, Decker T, Kalinsky K, Sopher G, Gao M, Hu H, Kuemmel S

doi: 10.1016/j.ejca.2025.115225

Related content

Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial

Human Epidermal Growth Factor Receptor 2 Loss Following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer

Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: A systematic review and updated meta-analysis

FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials

Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834

Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study

Impact of trifluridine/tipiracil plus bevacizumab on tumor shrinkage and depth of response in refractory metastatic colorectal cancer: analysis of the SUNLIGHT trial

Prospective validation of the modified metastatic colorectal cancer score (mCCS) in >600 patients with RAS-wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATE

Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials